SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brown KE. Human parvovirus B19 epidemiology and clinical manifestations. In: AndersonLJ, YoungNS, editors. Human parvovirus B19. Monograph of virology. Vol. 20. Basel: Karger; 1997. p. 4260.
  • 2
    Cherry JD. Parvovirus infections in children and adults. Adv Pediatr 1994; 46: 24569.
  • 3
    Török TJ. Unusual clinical manifestations reported in patients with parvovirus B19 infection. In: AndersonLJ, YoungNS, editors. Human parvovirus B19. Monograph of virology. Vol. 20. Basel: Karger; 1997. p. 6192.
  • 4
    Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Blase RM, et al. Chronic bone marrow failure due to persistent parvovirus B19 infection. N Engl J Med 1987; 317: 28794.
  • 5
    Pont J, Puchhammer-Stöckl E, Chott A, Popow-Kraupp T, Kienzer I, Postner G, et al. Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol 1992; 80: 1605.
  • 6
    Ozawa K, Young N. Characterisation of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol 1987; 62: 250811.
  • 7
    Söderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349: 10635.
  • 8
    Cassinotti P, Siegl G, Michel BA, Bruhlmann P. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. J Med Virol 1998; 56: 199204.
  • 9
    Agbandje-McKenna M, Rossmann MG. The structure of human parvovirus B19. In: AndersonLJ, YoungNS, editors. Human parvovirus B19. Monograph of virology. Vol. 20. Basel: Karger; 1997. p. 315.
  • 10
    Zadori Z, Szelei J, Lacoste MC, Li Y, Gariepy S, Raymond P, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001; 291302.
  • 11
    Dorsch S, Liebisch G, Kaufmann B, Von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 2002; 76: 20148.
  • 12
    Kurtzman GJ, Cohen B, Hanson G, Field AM, Oseas R, Blase RM, et al. Immune response to parvovirus B19 and an antibody defect in persistent viral infection. J Clin Invest 1989; 84: 111423.
  • 13
    Kurtzman GJ, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red cell aplasia of 10 years duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321: 51923.
  • 14
    Moffat S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72: 301828.
  • 15
    Gareus R, Gigler A, Hemauer A, Leruez-Ville M, Morinet F, Wolf H, et al. Characterization of cis-acting and NS1-responsive elements in the p6 promoter of parvovirus B19. J Virol 1998; 72: 60916.
  • 16
    Raab U, Bauer B, Gigler A, Beckenlehner K, Wolf H, Modrow S. Cellular transcription factors that interact with p6 promoter elements of parvovirus B19. J Gen Virol 2001; 82: 147380.
  • 17
    Von Poblotzki A, Hemauer A, Gigler A, Puchhammer-Stöckl E, Heinz FX, Pont J, et al. Detection of antibodies to the non-structural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Inf Diseases 1995; 172: 13569.
  • 18
    Hemauer A, Modrow S, Georgi J, Helmke K, Veith P, Lang B, et al. There is no correlation between polymyalgia rheumatica and acute parvovirus B19 infection [letter]. Ann Rheum Dis 1999; 58: 657.
  • 19
    Kerr JR, Cuniffe VS. Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection. Rheumatology 2000; 39: 9038.
  • 20
    Zakrzewska K, Azzi A, De Biasi E, Radossi P, De Santis R, Davoli PG, et al. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 2001; 65: 4027.
  • 21
    Lehmann HW, Kühner L, Beckenlehner K, Müller-Godeffroy E, Heide KG, Küster RM, et al. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. J Clin Virol 2002; 25: 13543.
  • 22
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31523.
  • 23
    Petty RE, Southwood TR, Baum J, Bheattay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis. J Rheumatol 1998; 25: 19913.
  • 24
    Knöll A, Louwen F, Kochanowski B, Plentz A, Stüssel J, Beckenlehner K, et al. Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR). J Med Virol 2002; 67: 25966.
  • 25
    Hemauer A, von Poblotzki A, Gigler A, Cassinotti P, Siegl G, Wolf H, et al. Sequence variability among different parvovirus B19 isolates. J Gen Virol 1996; 77: 17815.
  • 26
    Koch WC. Parvovirus B19. In: BehrmanRE, KliegmanRM, JensonHB, editors. Textbook of pediatrics. 16th ed. Philadelphia: W. B. Saunders; 2000: 9646.
  • 27
    Hemauer A, Gigler A, Searle K, Beckenlehner K, Raab U, Broliden K, et al. Seroprevalence of parvovirus B19 NS1-specific IgG in B19 infected and uninfected individuals and in infected pregnant women. J Med Virol 2000; 60: 4855.
  • 28
    Servant A, Laperche S, Lallemand F, Marinho V, de Saint Maur G, Meritet JF, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76: 912434.
  • 29
    Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53: 22932.
  • 30
    Cassinotti P, Siegl G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000; 19: 8867.
  • 31
    Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, et al. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997; 96: 354954.
  • 32
    Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D'Amati G, et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. CID 2000; 31: 659.
  • 33
    Eis-Hübinger AM, Reber U, Abdul-Nour T, Glatzel U, Lauschke H, Putz U. Evidence for persistence of parvovirus B19 DNA in livers of adults. J Med Virol 2001; 65: 395401.
  • 34
    Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72: 110.
  • 35
    Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcome of transfusion patients. Vox Sang 1998; 75: 97102.
  • 36
    Wakamatsu C, Takakura F, Kojima E, Kiriyama Y, Goto N, Matsumoto K, et al. Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sang 1999; 76: 1423.
  • 37
    Mimori A, Misaki Y, Hachiya T, Ito K, Kano S. Prevalence of antihuman parvovirus B19 IgG antibodies in patients with refractory rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis. Rheumatol Int 1994; 14: 8790.
  • 38
    Nocton JJ, Miller LC, Tucker LB, Schaller JG. Human parvovirus B19-associated arthritis in children. J Pediat 1993; 122: 18690.
  • 39
    Saal JG, Steidle M, Einsele H, Müller CA, Fritz P, Zacher J. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992; 12: 14751.
  • 40
    Stahl HD, Seidl B, Hubner B, Altrichter S, Pfeiffer R, Pustowoit B, et al. High incidence of parvovirus B19 DNA in synovial tissue of patients with undifferentiated mono- and oligoarthritis. Clin Rheumatol 2000; 19: 2816.
  • 41
    Stahl HD, Hubner B, Seidl B, Liebert UG, van der Heijden IM, Wilbrink B, et al. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann Rheum Dis 2000; 59: 3426.
  • 42
    Hokynar K, Brunstein J, Söderlund-Venermo M, Kiviluoto O, Partio EK, Konttinen Y, et al. Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue. J Gen Virol 2000; 81: 101725.
  • 43
    Ray NB, Nieva DR, Seftor EA, Khalkali-Ellis Z, Naides SJ. Induction of an invasive phenotype by human parvovirus B19 in normal human fibroblasts. Arthritis Rheum 2001; 44: 15826.
  • 44
    Kerr JR, Mattey DL, Thomson W, Poulton KV, Ollier WE. Association of acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. J Infect Dis 2002; 186: 44752.